Retatrutide in the US: The Triple Agonist, and What Is Actually Published

Retatrutide, development code LY3437943, is a synthetic 39-residue peptide developed by Eli Lilly, lipidated with a C20 fatty diacid to extend half-life to a once-weekly interval. Its distinguishing feature is receptor coverage: it is an agonist at the GIP, GLP-1 and glucagon receptors in a single molecule, where tirzepatide covers two of the three and semaglutide covers one.[3]

The glucagon-receptor arm is the mechanistically interesting one and the reason the compound is described as a triple agonist rather than a longer dual agonist. Glucagon-receptor engagement is associated with increased energy expenditure, which is a different lever from the appetite and gastric-emptying effects that carry the GLP-1 class.

Research Material

At around 4731 Da with a lipid side chain and non-natural residues, retatrutide is a genuinely difficult synthesis. That matters commercially in a way that a short peptide does not: the failure modes are truncation sequences, deletion sequences and incomplete lipidation, all of which produce material close enough in mass to pass a careless check and wrong enough to behave differently. A purity figure without an identity confirmation is close to meaningless at this molecular size.

Amino Acid Sequence

Chemical Structure

Unusually for a compound in research supply, retatrutide has published, peer-reviewed, randomized human data. Reported here as findings from named trials, not as claims about what the material in a vial will do:

• ·Phase 2, obesity. Jastreboff et al., New England Journal of Medicine 2023: a 48-week randomized, double-blind, placebo-controlled trial in adults with obesity. The trial met its primary endpoint across dose arms, with the highest arm reporting mean weight reduction substantially greater than placebo.[1]
• ·Phase 2, type 2 diabetes. Rosenstock et al., Lancet 2023: a 36-week randomized trial in adults with type 2 diabetes, reporting glycaemic and weight outcomes against placebo and against an active comparator.[2]
• ·Discovery and pharmacology. Coskun et al., Cell Metabolism 2022: the characterization paper for LY3437943, describing receptor activity, potency at each of the three receptors, and the preclinical basis for the once-weekly interval.[3]

Retatrutide has published phase 2 results. It has no published phase 3 dataset, no marketing authorization in the United States or anywhere else, and no regulator has cleared its full safety dossier. The published trials were conducted with pharmaceutical-grade material manufactured under GMP, in supervised clinical settings, at defined doses. None of those conditions attach to a research-grade vial.

the FDA has authorized no retatrutide product. The compound is a laboratory research material here and nothing else. Any supplier quoting trial percentages as if they were properties of the vial being sold has quietly substituted one thing for another.

For a peptide of this length and complexity, three certificate lines do the work. Identity by mass spectrometry, matched against the expected mass near 4731 Da, is the one that catches substitution with a cheaper GLP-1 analog, which is the most economically attractive form of fraud in this category. HPLC purity measures how much of the vial is the correct compound rather than synthesis by-products. Measured content against the labeled amount catches underfilling, which for a compound priced per milligram is a direct financial loss.

Every Eppix retatrutide lot is tested by Janoshik Analytical, with the certificate published before sale and verifiable on the laboratory's own database. Use the strength buttons under the certificate to move between strengths.

Published Certificate

Select strength

10mg20mg40mg50mg

Batch

RETA-CA-26E-01

Purity (HPLC)

99.637%

Measured content

11.76 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Domestic fulfillment is by FedEx, typically one to three business days across the United States, free over $200 USD, with card and PayPal checkout and mix-and-match pricing at 5 and 10 vials.

The mechanistic and evidential comparison against the dual agonist is set out in retatrutide vs tirzepatide. The tirzepatide sourcing guide is at buy tirzepatide in the US.

Available at Eppix Labs

Retatrutide (Triple Agonist)

10mg · 20mg · 40mg · 50mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $79.99 USDIn stock